Author:incardatheraadmin

July 24, 2018 In Publications

Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, lowdose intratracheal or intravenous administration

A.A. Marum, et al. | International Journal of Cardiology 2018 We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial fibrillation (AF) while reducing adverse ventricular effects. Methods: Flecainide was delivered via intratracheal administration at...

May 23, 2018 In Events

InCarda at San Francisco Business Times – Bay Area Biotech Forum

May 23, 2018 - San Francisco, CA At the SF Business Times Bay Area Biotech Forum, InCarda’s Dr. Grace Colon presented a company update to investors where she discussed the clinical challenges of Atrial Fibrillation and InCarda’s novel approach to treating it called, InRhythm (oral flecainide...

October 31, 2017 In Publications

Hand-held breath-actuated nebulizer for delivery of flecainide to the heart: Dose-concentration dependent pharmacokinetics and QRS interval prolongation of the inhaled flecainide in healthy volunteers.

Belardinelli | Circulation 2017; 136:A16836 Oral and IV routes for delivery of flecainide (FLEC) for acute cardioversion of atrial fibrillation (AF) have drawbacks: high doses (150-300 mg) and 2- to 4- hours wait time for cardioversion with oral dosing and hospitalization for IV administration. Studies in...

August 2, 2017 In Publications

A novel approach to deliver flecainide to the heart: A study in healthy volunteers to compare the cardiovascular effects of inhaled vs intravenous flecainide

Belardinelli | Circulation 2017; 136:A16888 Flecainide (FLEC) is effective for cardioversion of recentonset atrial fibrillation (AF). In dogs and pigs intratracheal instillation of FLEC is effective in terminating episodes of AF within minutes. The present study is part of a drug development program to use inhaled...

June 7, 2017 In Press Releases

InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation (PAF)

Flecainide administered via oral inhalation is well tolerated and elicits ECG changes suggestive of rapid drug delivery to heart Brisbane, California, June 7, 2017 – InCarda Therapeutics, Inc. (InCarda), a privately held biopharmaceutical company developing therapies for acute cardiovascular conditions via the inhalation route, today...